ANKARA – China has completed the construction of a research laboratory and workshop complex in the city of Wuhan for producing vaccines to combat coronavirus disease 2019 (Covid-19) pandemic, the state-run media said on Friday.
While the laboratory is capable of research and studying pathogenic virus vaccines, the workshop will produce over 100 million doses of the Covid-19 vaccine annually, reported Xinhua news agency, quoting the China National Pharmaceutical Group (Sinopharm).
The complex was earlier hit by the coronavirus pandemic, which first emerged in Wuhan city located in Central China’s Hubei province last December.
China National Biotec Group has also built another workshop in the capital Beijing which will also produce the anti-Covid-19 vaccines.
“The total annual production capacity of inactivated Covid-19 vaccines is expected to exceed 200 million doses, which will help ensure adequate supply,” the report cited Yang Xiaoming, president of the group, as saying.
Wuhan Institute of Biological Products had started the clinical trials of the vaccine to combat Covid-19 in April. So far, it has been tested on 1,120 volunteers aged between 18-59.
The report claimed, citing no officials, that the results of the trials “showed a good safety record” as “no severe adverse reactions were found.”
It noted the vaccine receivers “were inoculated two injections under different procedures and doses.”
“For those receiving two injections at an interval of 28 days, the seroconversion rate of neutralizing antibodies reached 100 percent,” claimed the report.
According to China’s National Health Commission, the country reported five new cases, including three imported and two indigenous, both from capital Beijing as the city has seen another wave of infections since the second week of June.
China so far recorded 83,542 pandemic cases with 4,634 deaths.
As many as 78,499 people have recovered. (Anadolu)
Asian countries interested in Russian-made drugs vs. Covid-19
In Moscow, Tass reported that Asian countries have expressed interest in Russian-produced drugs and vaccines against the coronavirus disease 2019 (Covid-19), Russian Deputy Foreign Minister Igor Morgulov said Thursday.
In an open interview with TASS, First Deputy Director General Mikhail Gusman, Morgulov said the Russian consumer rights watchdog actively cooperates with Asian states in bilateral and multilateral formats, namely within the Shanghai Cooperation Organization (SCO), BRICS (Brazil, Russia, India, China, and South Africa), East Asia Summit, and the Association of Southeast Asian Nations (Asean).
“We will surely carry on this work,” he said. “Asian partners have expressed a great deal of interest in the Russian experience of countering the pandemic, first and foremost in the developments related to the production of drugs aimed to combat this infection. And of course, a great deal of interest is expressed in the prospects of producing a vaccine against Covid-19.”
Morgulov added that Russia continues to aid many Asian states, sending medical equipment, test systems, and means of individual protection.
“Our mobile labs, for example, have been involved in the research of the coronavirus in the remote areas of Mongolia. We have similar labs based on the Russian-Vietnamese tropical center,” he said.
In late December 2019, Chinese officials notified the World Health Organization (WHO) about the outbreak of a previously unknown pneumonia in the city of Wuhan in central China.
Since then, cases of the novel coronavirus – named Covid-19 by the WHO – have been reported in every corner of the globe.
Last March 11, the WHO declared the coronavirus outbreak a pandemic. (TASS)